

Diffuse large B cell lymphoma - Pipeline Insight, 2021

<https://marketpublishers.com/r/D35CCDA91C18EN.html>

Date: June 2021

Pages: 60

Price: US\$ 2,500.00 (Single User License)

ID: D35CCDA91C18EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Diffuse large B cell lymphoma - Pipeline Insight, 2021," report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Diffuse large B cell lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Diffuse large B cell lymphoma Understanding

Diffuse large B cell lymphoma: Overview

Diffuse large B cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections. When you have a lymphoma, the abnormal lymphocytes build up in lymph nodes or other body organs. Each year about 5,500 people are diagnosed with DLBCL. This makes up about 40 out of 100 cases (40%) of NHL in adults. DLBCL is more common in males than females. Most people with DLBCL first notice painless lumps, often in their neck, armpit or groin. These are swollen (enlarged) lymph nodes. They usually grow quite quickly, over just a few weeks. Sometimes, DLBCL can develop in lymph nodes deep inside your body where they can't be felt from the outside. The

swollen nodes can form large lumps – known as ‘bulky disease’. DLBCL can also develop outside lymph nodes, called ‘extranodal’ disease. This affects around 1 in 5 people with DLBCL.

'Diffuse large B cell lymphoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diffuse large B cell lymphoma pipeline landscape is provided which includes the disease overview and Diffuse large B cell lymphoma treatment guidelines. The assessment part of the report embraces, in depth Diffuse large B cell lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diffuse large B cell lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Diffuse large B cell lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse large B cell lymphoma.

Diffuse large B cell lymphoma Emerging Drugs Chapters

This segment of the Diffuse large B cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diffuse large B cell lymphoma Emerging Drugs

Epcoritamab: Genmab

Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology. Genmab's DuoBody-CD3 technology is designed to

direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T cell mediated killing of lymphoma B cells. CD20 is a clinically validated therapeutic target, and is expressed on many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' broad oncology collaboration. Currently, it is in phase 3 stage of development for the treatment of Diffuse large B cell lymphoma.

Glofitamab: Roche

Glofitamab is an investigational CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B-cells and CD3 on the surface of T-cells. This dual targeting activates and redirects a patient's existing T-cells to engage and eliminate target B-cells by releasing cytotoxic proteins into the B-cells. Glofitamab is based on a novel structural format which we call '2:1', which refers to the structure of the antibody. It is engineered to have two 'Fab' regions which bind to CD20, and one 'Fab' region which binds to CD3. A robust clinical development programme for glofitamab is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with CD20-positive B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma, and other blood cancers.

Acalabrutinib: Acerta Pharma

Acalabrutinib is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.

AUTO 3: Autolus

AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. AUTO3 is currently in phase I/II stage of development for the treatment of diffuse large B cell lymphoma.

Abexinostat: Xynomic Pharmaceuticals

Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, it is in phase 2 stage of development for the treatment of Diffuse large B cell lymphoma.

Further product details are provided in the report..

Diffuse large B cell lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Diffuse large B cell lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diffuse large B cell lymphoma

There are approx. 80+ key companies which are developing the therapies for Diffuse large B cell lymphoma. The companies which have their Diffuse large B cell lymphoma drug candidates in the most advanced stage, i.e. phase III include, Genmab.

Phases

DelveInsight's report covers around 80+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Diffuse large B cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diffuse large B cell lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diffuse large B cell lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diffuse large B cell lymphoma drugs.

Diffuse large B cell lymphoma Report Insights

Diffuse large B cell lymphoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Diffuse large B cell lymphoma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Diffuse large B cell lymphoma drugs?

How many Diffuse large B cell lymphoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diffuse large B cell lymphoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diffuse large B cell lymphoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Diffuse large B cell lymphoma and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Genmab

Roche

Acerta Pharma

Autolus

Xynomic Pharmaceuticals

Genentech

Celgene

AbbVie

Mabion

Pharmacyclics LLC.

Shanghai Yingli Pharmaceutical

Philogen

Amgen

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

JW Therapeutics

Incyte Corporation

BeiGene

Miltenyi Biotec GmbH

Beijing InnoCare Pharma Tech Co., Ltd.

Bristol-Myers Squibb

Celleron Therapeutics

Otsuka Pharmaceutical

Curis, Inc.

Bayer

Kartos Therapeutics, Inc.

Shanghai Institute Of Biological Products

Novartis Pharmaceuticals

Constellation Pharmaceuticals

Secura Bio, Inc.

CytomX Therapeutics

Juno Therapeutics

Teneobio, Inc.

Telios Pharma, Inc.

Sorrento Therapeutics, Inc.

Curocell Inc.

TG Therapeutics, Inc.

Tessa Therapeutics

TCR2 Therapeutics

Plexxikon

Shattuck Labs, Inc.

MEI Pharma, Inc.

Boryung Pharmaceutical Co., Ltd

Sutro Biopharma, Inc

Newave Pharmaceutical Inc

Eden BioCell Ltd.

Adicet Bio, Inc

VelosBio Inc.

Seagen Inc.

Eisai Co Ltd

Nurix Therapeutics, Inc.

Prelude Therapeutics

Xencor

Key Products

Epcoritamab

Glofitamab

Acalabrutinib

AUTO 3

Abexinostat

Atezolizumab

Durvalumab

Venetoclax

MabionCD20

Ibrutinib

YY-20394

Mosunetuzumab

L19-IL2 fusion protein

Blinatumomab

Anlotinib Hydrochloride

JWCAR029

TQ-B3525

INCB053914

Zanubrutinib

MB-CART2019.1

ICP-022

Ipilimumab

Nivolumab

CXD101

OPB-111077

CUDC-907

Copanlisib

KRT-232

SIBP-02

VAY736

CPI-0209

Duvelisib

CX-2029

CC-97540

TNB-486

TL-895

STI-3031

Ublituximab

CRC01

CD30.CAR-T

TC-110 T Cells

PLX2853

SL-279252

ME-401

BR101801

STRO-001

LP-168

RPM CD19-mbIL15-CAR-T cells

ADI-001

VLS-101

SEA-TGT

Tazemetostat

NX-2127

PRT543

XmAb13676

Contents

Introduction

Executive Summary

Diffuse large B cell lymphoma: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Diffuse large B cell lymphoma – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Diffuse large B cell lymphoma companies' collaborations, Licensing, Acquisition -Deal

Value Trends

Diffuse large B cell lymphoma Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Epcoritamab: Genmab

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

Comparative Analysis

Abexinostat: Xynomic Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Early Stage Products (Phase I/II)

Comparative Analysis

AUTO 3: Autolus

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Inactive Products

Comparative Analysis

Diffuse large B cell lymphoma Key Companies

Diffuse large B cell lymphoma Key Products

Diffuse large B cell lymphoma- Unmet Needs

Diffuse large B cell lymphoma- Market Drivers and Barriers

Diffuse large B cell lymphoma- Future Perspectives and Conclusion

Diffuse large B cell lymphoma Analyst Views

Diffuse large B cell lymphoma Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Diffuse large B cell lymphoma

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Diffuse large B cell lymphoma
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Diffuse large B cell lymphoma - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/D35CCDA91C18EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D35CCDA91C18EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970